Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/11/2022 | $48.00 → $42.00 | Buy | Needham |
| 12/10/2021 | $50.00 → $48.00 | Buy | Needham |
8-K - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)
424B5 - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)
8-K - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that Brian Piekos has joined the Company as Chief Financial Officer (CFO). Mr. Piekos is an experienced public company CFO who brings a demonstrated track record of successfully leading companies across the biotechnology sector. "Brian's deep industry experience and expertise in managing financial and capital strategies makes him a strong addition to KalVista as we prepare for the commercialization of sebetralstat," said Ben Palleiko, Chief Executive Officer at KalVista. "I'm excited to welcome Brian to KalVista, as he shares our commitment to patients and a results-driven approach to business excellence." "I am excited to join
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that William C. Fairey has been appointed to the Company's Board of Directors, effective immediately. Mr. Fairey was most recently the Chief Commercial Officer at MyoKardia, Inc., a clinical stage biopharmaceutical company, and is a business leader with significant experience building markets and launching novel therapeutics to treat specialty and rare/orphan diseases. "We welcome Bill to our Board of Directors," said Ben Palleiko, CEO of KalVista. "His experience in commercial and me
- Sebetralstat Phase 3 KONFIDENT clinical trial met all endpoints and demonstrated a favorable safety profile as first oral on-demand therapy for hereditary angioedema - - CEO transition supports ongoing evolution into commercial company - KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided an operational update and released financial results for the third fiscal quarter ended January 31, 2024. "This has been an exciting and busy period for KalVista, as we achieved key milestones with the release of our phase 3 KONFIDENT data and th
4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)
4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)
4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)
4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)
4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)
4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)
– Sebetralstat 300 mg achieved beginning of symptom relief in 1.6 hours – – Safety profile comparable to placebo – – On track for submission of new drug application to U.S. FDA in the first half of 2024 – – Conference call to discuss trial results today at 8:30 a.m. ET – KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced positive results from the phase 3 KONFIDENT clinical trial demonstrating statistically and clinically significant efficacy of sebetralstat as oral on-demand therapy for hereditary angioedema (HAE). KONFIDENT was the l
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that the compensation committee of KalVista's board of directors granted twelve newly-hired employees inducement options to purchase an aggregate of 78,000 shares of KalVista common stock on November 1, 2024 as inducements material to each employee entering into employment with KalVista. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $10.61 per share, which was equal to the closing price of KalVista common stock on the grant date. One-fourth of the options vest on the one-year anniversary of the vesting commencement date and the remainder vest in equal monthly in
– First pre-approval royalty acquisition and first equity investment highlight evolving investment strategy – – Up to US$184 million investment brings capital deployment to over US$1 billion since IPO – – Long-term asset in new therapeutic area further increases portfolio duration and diversification – TORONTO, Nov. 4, 2024 /CNW/ - DRI Healthcare Trust (TSX:DHT) (TSX:DHT) (the "Trust"), a global leader in providing financing to advance innovation in the life sciences industry, has acquired a royalty interest in the worldwide net sales of all formulations of sebetralstat from KalVista Pharmaceuticals ("KalVista") for an aggregate purchase price of up to US$179 million, comprised of a US$100 m
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) ("KalVista") today announced the pricing of an underwritten offering of 5,500,000 shares of its common stock at a price of $10.00 per share to certain investors (the "Offering"). The gross proceeds to KalVista from the Offering are expected to be $55 million, before deducting underwriting discounts, commissions and other offering expenses payable by KalVista. Concurrently with the Offering, KalVista has entered into a securities purchase agreement with DRI Healthcare Acquisitions LP ("DRI"), an accredited investor affiliated with DRI Healthcare Trust, pursuant to which KalVista agreed to offer and sell and DRI agreed to purchase 500,000 shares o
HC Wainwright & Co. analyst Andrew Fein reiterates KalVista Pharma (NASDAQ:KALV) with a Buy and maintains $20 price target.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Piper Sandler cut the price target for Adobe Inc. (NASDAQ:ADBE) from $700 to $635. Piper Sandler analyst Brent Bracelin maintained an Overweight rating. Adobe shares fell 1.2% to close at $557.63 on Thursday. See how other analysts view this stock. Needham slashed the price target for KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) from $35 to $32. Needham analyst Serge Belanger maintained a Buy rating. KalVista Pharmaceuticals shares fell 0.6% to close at $12.50 on Thursday. See how other analysts vi
Needham analyst Serge Belanger maintains KalVista Pharma (NASDAQ:KALV) with a Buy and lowers the price target from $35 to $32.
SC 13D/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)
SC 13G/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)
SC 13D/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)
Needham reiterated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $42.00 from $48.00 previously
Needham reiterated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $48.00 from $50.00 previously
SVB Leerink resumed coverage of KalVista Pharmaceuticals with a rating of Buy